Is Eli Lilly’s Weight Loss Empire in Trouble? | Motley Fool

A man sitting at a desk looks at two monitors.

In the last two years Eli Lilly (LLY +0.80%) It has established itself as a leader in the weight loss market. This is thanks to the company’s Terzapatide, a compound sold under the name Zipbound as an anti-obesity drug (and Monjaro in the treatment of diabetes) that became the world’s best-selling drug in 2025. ZipBound … Read more